Tormod Kyrre Guren

Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer

Scott Kopetz, Axel Grothey, Rona Yaeger et al. · New England Journal of Medicine · 2019 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated <i>BRAF</i> V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

Josep Tabernero, Axel Grothey, Eric Van Cutsem et al. · Journal of Clinical Oncology · 2021 · 544 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study

Kjell Magne Tveit, Tormod Kyrre Guren, Bengt Glimelius et al. · Journal of Clinical Oncology · 2012 · 530 citations

Medicine, Oncology, Pharmacology +16

Chemotherapy or Liver Transplantation for Nonresectable Liver Metastases From Colorectal Cancer?

Svein Dueland, Tormod Kyrre Guren, Morten Hagness et al. · Annals of Surgery · 2014 · 207 citations

Medicine, Oncology, Surgery +17

Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first‐line oxaliplatin‐based treatment

Janne B Kjersem, Tone Ikdahl, Tormod Kyrre Guren et al. · Molecular Oncology · 2013 · 144 citations · Full text

Medicine, Oncology, Pharmacology +17